Injecting gene cocktail into mouse pancreas leads to humanlike tumors

April 5, 2018 by Will Sansom, University of Texas Health Science Center at San Antonio
UT Health San Antonio scientist Dr. Bruno Doiron has invented a unique method to generate, in mice, pancreatic tumors that resemble human pancreatic cancer. This will be a tool researchers can use to develop new drugs that extend patients' lives, and it is a tool researchers have not had at their disposal before. Credit: Dr. Bruno Doiron/UT Health San Antonio

Novel technology developed at UT Health San Antonio gives rise to mouse pancreatic tumors that have the same traits as human pancreatic cancer. A U.S. patent is pending on the invention.

The technology could revolutionize studies of pancreatic cancer initiation and progression and spur new drug development. An article published in the journal Carcinogenesis (Oxford University Press) describes this unique approach. Results of the research were made available online in November 2017 ahead of peer-review and print publication in February 2018.

Scientists study pancreatic cancer by genetically engineering mice to develop the disease or by transplanting tumors into rodents to test drug activity. In both cases, the resulting tumors provide an artificial, rather than true, picture of the human disease, said the technology's inventor, Bruno Doiron, Ph.D., of UT Health San Antonio.

"For a decade, we have failed in treating pancreatic cancer because we didn't have a good way to test new drugs," Dr. Doiron, an assistant professor in the Joe R. & Teresa Lozano Long School of Medicine, said.

Pancreatic cancer kills 95 percent of patients within five years of diagnosis. Advances in therapy have been negligible, with chemotherapies only able to extend survival by a few months. Need for a new study tool is therefore urgent.

Delivery method

Dr. Doiron and his lab team are injecting a modified virus into the adult mouse pancreas. The virus is a delivery vehicle for two pro-cancer molecules (called KrasG12D mutation and shRNA p53) that are present in human . Upon injection, the virus permeates the pancreas with these pro-cancer factors. The effect is contained; only the pancreas is altered by this molecular cocktail. When the mice reach 28 to 30 weeks of age, tumors develop that resemble human pancreatic cancer.

"I take the two major genetic mutations involved in human pancreatic cancer and inject them directly to the pancreas, and tumors develop in the adult mice," Dr. Doiron said. "This bypasses the artificial manipulation introduced by other methods, and spontaneous cancers develop that mimic those found in people."

The procedure is performed in mice that are not of any special breeding or stock. They are from many different parents. This ensures that the development of pancreatic cancer is in a random nature, the way it occurs in humans.

A step forward

The Carcinogenesis article "is an important paper for the field of pancreatic cancer, because it demonstrates that all previous methods of study are obsolete," Dr. Doiron said.

Obesity and diabetes are major risk factors for pancreatic cancer. The risk of pancreatic cancer is increased 1.5-fold in obese subjects and two- to threefold in people with diabetes. The new technology can be used to delve into this link.

"The prevalence of obesity and Type 2 diabetes has reached epidemic proportions during the last two decades in the U.S. and worldwide, and this may explain, in part, why the death rate from pancreatic cancer has not declined in the same way as it has for some other cancers," Dr. Doiron said.

Ruben A. Mesa, M.D., FACP, director of the Mays Cancer Center, the newly named center home to UT Health San Antonio MD Anderson Cancer Center, commented: "This important work by Dr. Doiron and colleagues will allow us to better predict which treatments for the devastating disease of will be effective. These discoveries are a much-needed advance on efforts to cure ."

Explore further: Mutations common in pancreatic CA, history of other cancers

More information: Bruno Doiron et al, A novel experimental model for human mixed acinar–ductal pancreatic cancer, Carcinogenesis (2017). DOI: 10.1093/carcin/bgx119

Related Stories

Mutations common in pancreatic CA, history of other cancers

February 7, 2018
(HealthDay)—A substantial proportion of individuals with pancreatic cancer and a history of other hereditary breast and ovarian cancer (HBOC)- or Lynch syndrome (LS)-related cancers have mutations in a prostate cancer susceptibility ...

Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target

October 17, 2016
Researchers have found that a protein called SLC6A14 is overexpressed by several fold in pancreatic tumors taken from patients and in cancerous pancreatic cells lines compared with normal pancreatic tissue or normal pancreatic ...

Searching out pancreatic cancer risk

December 8, 2017
A prospective study by Wei Zheng, Ph.D., M.D., and colleagues delivers the first direct epidemiological evidence that increased production of a chemical compound called prostaglandin E2 (PGE2), as measured by metabolites ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

Study pinpoints gene's role in pancreatic cancer

August 11, 2017
Pancreatic cancer is a particularly deadly form of disease, and patients have few options for effective treatment. But a new Yale-led study has identified a gene that is critical to pancreatic cancer cell growth, revealing ...

Do pancreatic cysts become cancerous?

November 21, 2017
What is a pancreatic cyst?

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.